Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report (UPDATED)
Portfolio Pulse from Vandana Singh
A new report from the Access to Medicine Foundation indicates that despite efforts by generic drug companies, many vulnerable patients still lack access to essential medicines. Of the 50 products examined from five major generic drug firms, only one had a pricing strategy aligned with patients' affordability in low-to-middle-income nations. The companies include Cipla Ltd, Hikma Pharmaceuticals Plc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), and Viatris Inc (NASDAQ: VTRS).
September 26, 2023 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Teva Pharmaceutical Industries Ltd announced in May its intentions to halt the production of certain less lucrative drugs. This could potentially impact the company's revenue and stock price.
Teva's decision to halt the production of certain drugs could lead to a decrease in revenue, which could negatively impact the company's stock price. Additionally, this decision could affect the company's reputation, particularly if these drugs are essential to certain patient populations.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Viatris Inc is one of the five generic drug companies highlighted in the report for their efforts to broaden access to vital medicines. However, the report indicates that many vulnerable patients remain underserved.
While Viatris is making efforts to broaden access to vital medicines, the report indicates that many vulnerable patients remain underserved. This could potentially impact the company's reputation and stock price, depending on how investors interpret this information.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70